OncoMed Pharmaceuticals Inc. (OMED) Trading Down 6.2%
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) shares traded down 6.2% during mid-day trading on Wednesday . The stock traded as low as $10.01 and last traded at $10.17, with a volume of 148,672 shares trading hands. The stock had previously closed at $10.84.
Several research analysts recently weighed in on the stock. Mizuho reduced their price objective on shares of OncoMed Pharmaceuticals from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Wednesday, June 1st. Cantor Fitzgerald reissued a “buy” rating on shares of OncoMed Pharmaceuticals in a research note on Wednesday, June 8th. Jefferies Group reissued a “buy” rating and set a $15.00 price objective (down previously from $16.00) on shares of OncoMed Pharmaceuticals in a research note on Friday, May 6th. Zacks Investment Research lowered shares of OncoMed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10th. Finally, Leerink Swann lifted their price objective on shares of OncoMed Pharmaceuticals from $11.00 to $13.00 and gave the stock a “market perform” rating in a research note on Thursday, May 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. OncoMed Pharmaceuticals currently has an average rating of “Buy” and an average target price of $19.29.
The company’s market cap is $315.00 million. The company has a 50 day moving average of $11.59 and a 200 day moving average of $11.53.
OncoMed Pharmaceuticals (NASDAQ:OMED) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by $0.10. The business earned $6.67 million during the quarter, compared to analysts’ expectations of $8.09 million. The company’s quarterly revenue was up 42.2% on a year-over-year basis. During the same period last year, the firm posted ($0.72) earnings per share. Analysts anticipate that OncoMed Pharmaceuticals Inc. will post ($3.39) earnings per share for the current fiscal year.
An institutional investor recently bought a new position in OncoMed Pharmaceuticals stock. Jennison Associates LLC bought a new stake in OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 89,546 shares of the biopharmaceutical company’s stock, valued at approximately $2,018,000. Jennison Associates LLC owned 0.30% of OncoMed Pharmaceuticals at the end of the most recent reporting period.
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.